LRRK2 inhibitors LRRK2
-
Double East-Asian LRRK2 variant carriers (p.G2385R + p.R1628P) show ~4.3× PD odds and markedly increased LRRK2 kinase activity, identifying them as the highest-priority subgroup for LRRK2 inhibitor trials.
Carriers of two risk variants had OR = 4.30 (95% CI 1.59–11.6; P=0.004) versus noncarriers... supported by recent functional data showing that double-variant carriers have markedly increased pRab10Thr73 phosphorylation compared with controls, consistent with heightened LRRK2 pathway activation.